ArticleJournal of cellular and molecular medicine2025
MiR-20a-5p Inhibits Bladder Cancer Proliferation and Migration by Targeting KPNA2.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- KPNA2 knockdown suppresses gastric cancer progression through modulation of the β-catenin/EMT signaling axis, inducing cell cycle arrest, apoptosis, and reduced metastatic capacity.Journal of molecular histology · 2026Article
- Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition.Journal of experimental & clinical cancer research : CR · 2025Article
- MiR-20a-5p Inhibits Bladder Cancer Proliferation and Migration by Targeting KPNA2.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bladder cancer (BC) is one of the 10 most common cancers in the world, and its recurrence and metastasis are the main causes of death in BC patients. Exploring the molecular mechanisms of BC pathogenesis and searching for new prognostic markers and therapeutic targets are important for improving patient prognosis. KPNA2 was found to be a potential oncogene in different malignant tumours, as demonstrated in our previous study. To better understand the mechanisms associated with BC development, we investigated the inhibitory effect of miR-20a-5p on the oncogene KPNA2. RNA-seq data from BC patients were downloaded through the TCGA database for bioinformatics analysis, including gene expression, co-expression analysis, GSEA, nomogram modelling, functional enrichment analysis, WGCNA, GO and KEGG to assess the potential biological functions of miR-20a-5p in BC. Subsequently, we further verified the expression of miR-20a-5p in BC cells by RT-qPCR, and in vitro experiments were performed to investigate the effects of this gene on BC cell proliferation and migration. MiR-20a-5p was downregulated in BC tissues and cells. Kaplan-Meier analysis revealed that the higher the expression of miR-20a-5p in patients, the higher the survival rate of BC patients. MiR-20a-5p overexpression inhibited the proliferation and migration of BC cells. In addition, miR-20a-5p can directly bind to nuclear transporter protein α2 (KPNA2) in cells, targeting and regulating the expression of KPNA2. These findings indicate that miR-20a-5p targeting KPNA2 adversely affects the proliferation and migration of BC cells, suggesting that miR-20a-5p may be an attractive target in BC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.